Payment overview · 2025
General Payments
$229.54
12 reported records · 8 companies
Healthcare provider profile · identity verified
Caleb J Workman, DO
Allopathic & Osteopathic Physicians|Family Medicine · BECKLEY, WV · NPI 1891921136
Verified facts
What the public records show
CMS Open Payments records show Caleb J Workman, DO received $229.54 in general payments during 2025 across 12 reported records.
Novo Nordisk Inc accounted for 22.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 177 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $50.48 | 22.0% | 3 | 2025 |
| Tonix Medicines, Inc. | Unresolved — no canonical attribution shown | $47.98 | 20.9% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $38.73 | 16.9% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $22.73 | 9.9% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $19.16 | 8.3% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $18.67 | 8.1% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $16.20 | 7.1% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $15.59 | 6.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $229.54 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TONMYA Normalized: tonmya |
Drug | Tonix Medicines, Inc. | $47.98 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $38.73 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $36.87 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 2 Normalized: freestyle libre 2 |
Device | Abbott Laboratories | $22.73 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $19.16 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $18.70 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $18.67 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $18.67 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $16.20 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $15.59 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $13.61 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 108 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 177 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
51 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
43 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
177 | 35 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
108 | 29 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
13 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 459 | 122 |
| Amlodipine Besylate | Amlodipine Besylate | 439 | 122 |
| Levothyroxine Sodium | Levothyroxine Sodium | 417 | 104 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 304 | 89 |
| Pantoprazole Sodium | Pantoprazole Sodium | 272 | 79 |
| Omeprazole | Omeprazole | 263 | 61 |
| Metoprolol Succinate | Metoprolol Succinate | 260 | 82 |
| Furosemide | Furosemide | 234 | 69 |
| Gabapentin | Gabapentin | 223 | 42 |
| Potassium Chloride | Potassium Chloride | 219 | 71 |
| Lisinopril | Lisinopril | 211 | 60 |
| Metformin Hcl | Metformin Hcl | 202 | 59 |
| Montelukast Sodium | Montelukast Sodium | 193 | 59 |
| Ozempic | Semaglutide | 177 | 35 |
| Hydrochlorothiazide | Hydrochlorothiazide | 174 | 39 |
| Losartan Potassium | Losartan Potassium | 174 | 57 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 172 | 56 |
| Clopidogrel | Clopidogrel Bisulfate | 150 | 41 |
| Tamsulosin Hcl | Tamsulosin Hcl | 132 | 36 |
| Fluticasone Propionate | Fluticasone Propionate | 118 | 36 |
| Trazodone Hcl | Trazodone Hcl | 117 | 30 |
| Ibuprofen | Ibuprofen | 110 | 30 |
| Pravastatin Sodium | Pravastatin Sodium | 109 | 31 |
| Eliquis | Apixaban | 108 | 29 |
| Famotidine | Famotidine | 100 | 27 |
| Tramadol Hcl | Tramadol Hcl | 100 | 26 |
| Alendronate Sodium | Alendronate Sodium | 99 | 27 |
| Metoprolol Tartrate | Metoprolol Tartrate | 91 | 24 |
| Tizanidine Hcl | Tizanidine Hcl | 91 | 39 |
| Meloxicam | Meloxicam | 90 | 27 |
| Simvastatin | Simvastatin | 86 | 20 |
| Diclofenac Sodium | Diclofenac Sodium | 84 | 27 |
| Valsartan | Valsartan | 82 | 24 |
| Fenofibrate | Fenofibrate | 81 | 22 |
| Hydralazine Hcl | Hydralazine Hcl | 81 | 26 |
| Escitalopram Oxalate | Escitalopram Oxalate | 80 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 77 | 22 |
| Ezetimibe | Ezetimibe | 77 | 20 |
| Allopurinol | Allopurinol | 72 | 15 |
| Glipizide | Glipizide | 69 | 19 |
| Naproxen | Naproxen | 69 | 18 |
| Doxycycline Hyclate | Doxycycline Hyclate | 60 | 49 |
| Finasteride | Finasteride | 53 | 20 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 52 | 12 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 52 | 14 |
| Synthroid | Levothyroxine Sodium | 51 | 15 |
| Nifedipine Er | Nifedipine | 50 | 12 |
| Tresiba Flextouch U-100 | Insulin Degludec | 49 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 48 | 12 |
| Carvedilol | Carvedilol | 47 | 16 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 44 | 15 |
| Jardiance | Empagliflozin | 43 | 11 |
| Ibu | Ibuprofen | 41 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 41 | 12 |
| Lorazepam | Lorazepam | 41 | suppressed |
| Spironolactone | Spironolactone | 41 | 15 |
| Alprazolam | Alprazolam | 40 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 40 | 11 |
| Celecoxib | Celecoxib | 39 | 16 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 39 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 38 | 12 |
| Meclizine Hcl | Meclizine Hcl | 38 | 19 |
| Methylprednisolone | Methylprednisolone | 38 | 32 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 35 | 26 |
| Clonidine Hcl | Clonidine Hcl | 35 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 35 | suppressed |
| Januvia | Sitagliptin Phosphate | 35 | 12 |
| Metformin Hcl Er | Metformin Hcl | 35 | 12 |
| Glipizide Er | Glipizide | 34 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 33 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 33 | suppressed |
| Cefdinir | Cefdinir | 32 | 28 |
| Donepezil Hcl | Donepezil Hcl | 32 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 32 | 13 |
| Ventolin Hfa | Albuterol Sulfate | 32 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 32 | 11 |
| Warfarin Sodium | Warfarin Sodium | 32 | suppressed |
| Prednisone | Prednisone | 30 | 18 |
| Xarelto | Rivaroxaban | 30 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 29 | suppressed |
| Ondansetron Odt | Ondansetron | 29 | 15 |
| Bupropion Xl | Bupropion Hcl | 28 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 28 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 28 | 11 |
| Atenolol | Atenolol | 27 | suppressed |
| Torsemide | Torsemide | 27 | suppressed |
| Baclofen | Baclofen | 26 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 26 | suppressed |
| Novolog Flexpen | Insulin Aspart | 26 | suppressed |
| Tradjenta | Linagliptin | 26 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 25 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 25 | suppressed |
| Lovastatin | Lovastatin | 25 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Klor-Con M20 | Potassium Chloride | 24 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 24 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 23 | suppressed |
| Mupirocin | Mupirocin | 23 | 16 |
| Symbicort | Budesonide/Formoterol Fumarate | 23 | suppressed |
| Colchicine | Colchicine | 22 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 20 | suppressed |
| Myrbetriq | Mirabegron | 20 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 20 | suppressed |
| Nitroglycerin | Nitroglycerin | 19 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 19 | suppressed |
| Pregabalin | Pregabalin | 19 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 19 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 19 | 11 |
| Nystatin | Nystatin | 18 | 11 |
| Ranolazine Er | Ranolazine | 18 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 18 | suppressed |
| Cilostazol | Cilostazol | 17 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 17 | suppressed |
| Mounjaro | Tirzepatide | 17 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 17 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 17 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 16 | suppressed |
| Diazepam | Diazepam | 16 | suppressed |
| Entresto | Sacubitril/Valsartan | 16 | suppressed |
| Gemfibrozil | Gemfibrozil | 16 | suppressed |
| Glimepiride | Glimepiride | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 16 | 12 |
| Propranolol Hcl Er | Propranolol Hcl | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | 13 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Sucralfate | Sucralfate | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Cephalexin | Cephalexin | 12 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 12 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 12 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 11 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 11 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 11 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Erythromycin | Erythromycin Base | 11 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | 11 |
| Metronidazole | Metronidazole | 11 | suppressed |
| Nabumetone | Nabumetone | 11 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
| Pentoxifylline | Pentoxifylline | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $229.54 · 12 records | Novo Nordisk Inc | AIRSUPRA, Dexcom G6 Transmitter, ELIQUIS, FREESTYLE LIBRE 2, LINZESS, MOUNJARO, NURTEC ODT, Ozempic, Rybelsus, TONMYA, Wegovy | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error